Direct-to-consumer advertising is being blamed in large part for the pharmaceutical industry's eroding reputation. Some of the industry's oldest friends in Congress are proposing moratoriums on DTC ads. PhRMA's DTC guidelines may have mollified Congress and FDA for now. However, with the hundreds of billions of dollars lined up for the Medicare drug benefit, CMS could be the newest player in restricting DTC.
By Ramsey Baghdadi
Direct-to-consumer advertisements "create an artificial demand…[and] needlessly and wastefully drive up your health costs," noted the Senator on the legislative...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Vertex said it reached “a broad reimbursement agreement” with the National Health Service for its once-daily, triple combination treatment for cystic fibrosis. As for reimbursement in the rest of Europe, the company is targeting Ireland, Denmark and Germany next.
China has announced a raft of new measures to encourage innovative drug development across the product life cycle, including using insurance data to differentiate new therapies and applying commercial insurance to selected novel products.
Insurance trade groups warned that the Big Beautiful Bill destabilize Medicaid and result in the largest ever roll-back in health care coverage in the US.
The creation of a single national formulary for medicines prescribing that could impact industry is among the action points in the UK government’s new 10-year health plan for the National Health Service in England.
Amid the wait for an action plan to apply AI tools to drug regulation at the national level in China, capital city Beijing has released its own vision of scenarios for the technology in the healthcare sector.
Senate appropriators also put FDA on notice regarding recent meetings and compliance with the Federal Advisory Committees Act, signal positive news on rare pediatric diseases, and offer hints of other agency areas they have close eyes on.
US FDA's 25 novel approvals in 2025 fell short of the agency's five-year average count, driven by a drop in drugs center approvals; 45 user fee goals remain in second half of year.
